A cycloruthenated complex, ruthenium (II) Z (RuZ) overcomes and multidrug resistance in cancer cells: A pivotal breakthrough.
作者信息
Cao Luqi, Xie Yuhao, Chen Zhesheng, Ashby Charles R
机构信息
Institute for Biotechnology, St. John's University, Queens, New York 11439, USA.
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, USA.
出版信息
J Transl Int Med. 2023 Jul 5;11(2):95-97. doi: 10.2478/jtim-2023-0081. eCollection 2023 Jul.
Abstract
摘要
相似文献
1
A cycloruthenated complex, ruthenium (II) Z (RuZ) overcomes and multidrug resistance in cancer cells: A pivotal breakthrough.一种环金属化钌配合物，钌（II）Z（RuZ）克服了癌细胞中的多药耐药性：一项关键突破。
J Transl Int Med. 2023 Jul 5;11(2):95-97. doi: 10.2478/jtim-2023-0081. eCollection 2023 Jul.
2
Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro.钌配合物 HB324 通过上调 Harakiri 诱导神经母细胞瘤细胞凋亡并克服顺铂耐药性。
Int J Mol Sci. 2023 Jan 4;24(2):952. doi: 10.3390/ijms24020952.
3
Cycloruthenated complexes: pH-dependent reversible cyclometallation and reactions with nitrite at octahedral ruthenium centers.环钌配合物：八面体钌中心的pH依赖性可逆环金属化及与亚硝酸盐的反应
Dalton Trans. 2016 Apr 25;45(17):7450-9. doi: 10.1039/c6dt00576d.
4
Ruthenium(II)-catalyzed C-H activation with isocyanates: a versatile route to phthalimides.钌（II）催化的异氰酸酯参与的C-H活化反应：一种合成邻苯二甲酰亚胺的通用方法。
Chemistry. 2014 Oct 20;20(43):13932-6. doi: 10.1002/chem.201404261. Epub 2014 Sep 8.
5
Dynamic dimer-monomer equilibrium in a cycloruthenated complex of [Re(η-CH)].[Re(η-CH)]的环钌配合物中的动态二聚体-单体平衡
Chem Commun (Camb). 2020 Sep 15;56(73):10658-10661. doi: 10.1039/d0cc04180g.
6
A mercuric ensemble based on a cycloruthenated complex as a visual probe for iodide in aqueous solution.一种基于环钌配合物的汞系综作为水溶液中碘化物的可视化探针。
Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:468-74. doi: 10.1016/j.saa.2015.07.087. Epub 2015 Jul 26.
7
Ruthenium(II)-Catalyzed α-Fluoroalkenylation of Oxime Ethers with -Difluorostyrenes C-H Activation and C-F Cleavage.钌（II）催化肟醚与 -二氟苯乙烯的α-氟烯基化反应：C-H 活化和 C-F 断裂
J Org Chem. 2020 Oct 2;85(19):12670-12681. doi: 10.1021/acs.joc.0c01842. Epub 2020 Sep 14.
8
An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.一种有机钌配合物通过多种机制克服 ABCG2 介导的多药耐药性。
Chem Commun (Camb). 2019 Mar 26;55(26):3833-3836. doi: 10.1039/c9cc00882a.
9
Ru(II)-Catalyzed β-Carboline Directed C-H Arylation and Isolation of Its Cycloruthenated Intermediates.钌（II）催化的β-咔啉导向的C-H芳基化反应及其环钌化中间体的分离
J Org Chem. 2015 Jun 5;80(11):5532-45. doi: 10.1021/acs.joc.5b00411. Epub 2015 Apr 21.
10
Functionalized Multiwalled Carbon Nanotubes as Carriers of Ruthenium Complexes to Antagonize Cancer Multidrug Resistance and Radioresistance.功能化多壁碳纳米管作为钌配合物的载体以对抗癌症多药耐药性和放射抗性。
ACS Appl Mater Interfaces. 2015 Jul 15;7(27):14933-45. doi: 10.1021/acsami.5b03739. Epub 2015 Jul 6.
引用本文的文献
1
Multiple signaling pathways in the frontiers of lung cancer progression.肺癌进展前沿的多种信号通路。
Front Immunol. 2025 Jun 10;16:1593793. doi: 10.3389/fimmu.2025.1593793. eCollection 2025.
2
Lactic acid metabolism: gynecological cancer's Achilles' heel.乳酸代谢：妇科癌症的致命弱点。
Discov Oncol. 2025 May 2;16(1):657. doi: 10.1007/s12672-025-02364-y.
3
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.解码肿瘤血管生成：抗癌策略中的途径、机制及未来方向
Biomark Res. 2025 Apr 18;13(1):62. doi: 10.1186/s40364-025-00779-x.
4
Matrix stiffness regulates NPC invasiveness by modulating a mechanoresponsive TRPV4-Nox4-IL-8 signaling axis.基质硬度通过调节机械反应性TRPV4-Nox4-IL-8信号轴来调控神经前体细胞的侵袭性。
J Cancer. 2025 Jan 13;16(4):1324-1334. doi: 10.7150/jca.104235. eCollection 2025.
5
iRGD-TRP-PK1-modified red blood cell membrane vesicles as a new chemotherapeutic drug delivery and targeting system in head and neck cancer.iRGD-TRP-PK1修饰的红细胞膜囊泡作为头颈癌新型化疗药物递送与靶向系统
Theranostics. 2025 Jan 1;15(1):86-102. doi: 10.7150/thno.99481. eCollection 2025.
6
Prognostic and Immunological Role of Cuproptosis-Related Gene MTF1 in Pan-Cancer.铜死亡相关基因MTF1在泛癌中的预后及免疫作用
J Cancer. 2024 Sep 9;15(17):5786-5809. doi: 10.7150/jca.98749. eCollection 2024.
本文引用的文献
1
Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers.环钌自组装与代谢抑制协同作用，高效克服癌症多药耐药性。
Adv Mater. 2022 Jan;34(1):e2100245. doi: 10.1002/adma.202100245. Epub 2021 Oct 24.
2
A view on drug resistance in cancer.癌症耐药性的观点。
Nature. 2019 Nov;575(7782):299-309. doi: 10.1038/s41586-019-1730-1. Epub 2019 Nov 13.
3
Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies.克服多药耐药性的非凋亡依赖性有机钌抗癌复合物：自组装和表型筛选策略
Chem Sci. 2017 May 1;8(5):3641-3649. doi: 10.1039/c7sc00497d. Epub 2017 Feb 28.
4
Structure of the human multidrug transporter ABCG2.人源多药耐药相关蛋白 ABCG2 的结构。
Nature. 2017 Jun 22;546(7659):504-509. doi: 10.1038/nature22345. Epub 2017 May 29.
5
Doxorubicin pathways: pharmacodynamics and adverse effects.多柔比星作用途径：药效学与不良反应
Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56.
6
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.通过单步阿霉素筛选的癌细胞通过表观遗传变化过度表达ABCG2药物转运蛋白。
Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.
Zotero 插件